Please read Dr. McGovern’s article in AIDS Research and Human Retroviruses titled, “Global Imbalances in Funding Sources for HIV Randomized Control Trials.”
Improving access to grant funding is a critical aspect of strengthening research capacity outside of higher income settings, particularly in HIV/AIDS where randomized control trials (RCTs) that require substantial resources are common. In this article, we assessed recent RCTs to examine variation in how studies were funded, depending on study location and the countries where publication authors were based. We conducted a PubMed literature review to identify RCTs with HIV status or viral load endpoints published in 2019 and 2020, then analyzed cross-tabulations of funding sources by study characteristics. One hundred sixteen publications met the inclusion criteria. Research in higher income countries was most likely to be funded by biotech/pharmaceutical companies, whereas research in lower- and middle-income countries was most likely to be funded by U.S. government sources To read the full article.
Global Imbalances in Funding Sources for HIV Randomized Control Trials. Daniel Owoicholofu John, Peng Wang, Yaya Togo, Mark McGovern. AIDS Res Hum Retroviruses. 2023 Jan 10. PMID: 36401360 PMCID: PMC9942170 DOI: 10.1089/AID.2022.0068